Mounjaro And Oral Contraceptive Pills

Mounjaro And Oral Contraceptive Pills

Excessive fat accumulation, denoted as overweight and obesity, poses health risks, with a body mass index (BMI) exceeding 25 indicating overweight and 30 denoting obesity.

Advancements in neuroendocrine and gastrointestinal control of appetite and energy expenditure have led to medications facilitating weight loss maintenance. Notably, long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, approved by the FDA for type 2 diabetes treatment, have garnered interest.

However, the pursuit of swift weight loss and improved blood sugar control carries an unforeseen consequence. Many women with obesity, using oral contraceptives, may not be aware that these medications, particularly tirzepatide (Mounjaro), can impede the absorption and efficacy of birth control pills, elevating the risk of unintended pregnancies.

Mounjaro’s package insert recommends females on oral contraceptives to switch to a non-oral method or incorporate a barrier contraceptive for four weeks post-initiation and after each dose escalation.

Share

Leave A Reply

    5/5 - (2 votes)